Quantcast

Latest Liposome Stories

2014-09-29 23:08:06

MitoSynergy Completes Double-Blinded Clinical Study for Proprietary Ingredient, Cunermuspir, Announces Results of Study at SupplySide West 2014 at Booth #20016 Los Angeles (PRWEB) September 29, 2014 MitoSynergy is proud to announce the world’s first biocompatible copper chelate. This proprietary copper B3 chelate, Cunermuspir, provides nutrition with the optimum blend of oxidative state and proper chelation, for better delivery and absorption into the body. Reports have shown that the...

2014-09-09 20:25:09

LAS VEGAS, Sept. 9, 2014 /PRNewswire/ -- Altogen Biosystems (www.altogen.com), a manufacturer of reagents for biological research, offers a broad range of animal in vivo transfection kits targeted to a specific tissue type. The Company provides transfection reagents that enable tissue-targeted delivery of plasmid DNA expression vectors, small RNA therapeutic molecules (siRNA and microRNA), and proteins (http://www.altogen.com/mirna.php). In vivo transfection kits are laboratory tested...

2014-07-17 04:20:54

Encapsula NanoSciences, a company specializing in liposome research and development, announces the release of two new liposome-­based products for consumer use NASHVILLE, Tenn., July 17, 2014 /PRNewswire/ -- Encapsula NanoSciences announces the release of two new liposome ­based products? Curcusome® and Taurosome(TM). Curcusome® or liposomal curcumin is a nutraceutical supplement that comes innovatively packaged in a powder ­release cap for consumer ease. Taurosome(TM) or...

2014-06-20 08:24:10

-- Transaction Forms Fully-Integrated Oncology Discovery and Development Company LAWRENCEVILLE, N.J., June 20, 2014 /PRNewswire/ -- Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other...

2014-06-10 08:29:59

- Transaction Forms Fully-Integrated Oncology Discovery and Development Company LAWRENCEVILLE, N.J. and HUNTSVILLE, Ala., June 10, 2014 /PRNewswire/ -- Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase...

2014-05-22 10:47:01

The Institute for Genomic Biology When Associate Professor of Chemical and Biomolecular Engineering Hyunjoon Kong, graduate student Cartney Smith, and colleagues set out to improve MR imaging (MRI), they turned current contrast agent technology on its head—or rather, they turned it inside out.  The new compound they designed in collaboration with Roger Adams Professor of Chemistry Steven C. Zimmerman is not only more effective, but also self-assembling. Kong is a member of the...

2014-05-21 11:59:58

National Institute of Standards and Technology (NIST) When the English author Sir Francis Bacon wrote "The world's a bubble" in 1629, it's a safe bet he wasn't thinking about microfluidics. However, for a research team led by scientists at the National Institute of Standards and Technology (NIST), Bacon's words could not be truer. Since 2004, their world has revolved around the development of increasingly sophisticated microfluidic devices to produce liquid-filled "bubbles" called...

2014-05-09 20:11:01

NCSU Biomedical engineering researchers have developed an anti-cancer drug delivery method that essentially smuggles the drug into a cancer cell before triggering its release. The method can be likened to keeping a cancer-killing bomb and its detonator separate until they are inside a cancer cell, where they then combine to destroy the cell. “This is an efficient, fast-acting way of delivering drugs to cancer cells and triggering cell death,” says Dr. Ran Mo, lead author of a paper...

2014-05-09 19:06:35

Massachusetts Institute of Technology Nanoparticles that stagger delivery of 2 drugs knock out aggressive tumors in mice MIT researchers have devised a novel cancer treatment that destroys tumor cells by first disarming their defenses, then hitting them with a lethal dose of DNA damage. In studies with mice, the research team showed that this one-two punch, which relies on a nanoparticle that carries two drugs and releases them at different times, dramatically shrinks lung and breast...

2014-04-29 23:21:49

Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with Insmed Incorporated for the manufacture of ARIKAYCE, liposomal amikacin for inhalation. Mississauga, Ontario (PRWEB) April 29, 2014 Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with Insmed Incorporated for the manufacture of ARIKAYCE, liposomal amikacin for inhalation. Therapure Biomanufacturing is an...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin